Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 1/2023

09.01.2023 | Original Paper

Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience

verfasst von: Fernanda Bueno, Anabella Smulever, Inés Califano, Jorgelina Guerra, Andrés Del Grecco, Juan Manuel Carrera, Raúl Giglio, Manglio Rizzo, Alejo Lingua, Ana Voogd, María del Carmen Negueruela, Erika Abelleira, Fabian Pitoia

Erschienen in: Endocrine | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To present our real-life experience with dabrafenib and trametinib (D-T) treatment in patients with BRAF V600E-mutated ATC in Argentina.

Patients y methods

We included five patients from four different hospitals. The median age was 70 years, and 60% were male. The performance status at diagnosis was grade 0 in 60% and grade 2 in 40% of patients. Four patients could undergo total thyroidectomy; in one of them, surgical treatment was amenable due to the indication of D-T as neoadjuvant therapy. From the total cohort, the best response to treatment was complete response in 40%, partial response in 20%, and stable disease in 20%. The median duration of response was 20 weeks, ranging from 16 to 92 weeks. All patients experienced at least one adverse event (AE). Grade ≥3 AEs were observed in two (40%) patients. They were upper gastrointestinal bleeding and subclavian vein thrombosis. The median follow-up was 20 weeks (range: 16 to 92).

Conclusion

This report contributes to illustrate the feasibility and effectiveness of D-T treatment in five patients with loco-regionally advanced and metastatic BRAF V600E-mutated ATC in a real-life setting. A multidisciplinary approach and rapid molecular-tailored testing are essential to begin this therapeutic option.
Literatur
1.
R.L. Neff, W.B. Farrar, R.T. Kloos, B.D. Kenneth, Anaplastic thyroid carcinoma. Endocrinol. Metab. Clin. North Am. 37, 525–538 (2008)CrossRefPubMed
2.
L.M. Caronia, J.E. Phay, M.H. Shah, Role of BRAF in thyroid oncogenesis. Clin. Cancer Res 17, 7511–7517 (2011)CrossRefPubMed
3.
4.
E. Kebebew, F.S. Greenspan, O.H. Clark, K.A. Woeber, A. McMillan, Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103, 1330–1335 (2005)CrossRefPubMed
5.
J.P. Pierie, A. Muzikansky, R.D. Gaz, W.C. Faquin, M.J. Ott, The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann. Surg. Oncol. 9, 57–64 (2022)CrossRef
6.
E. Molinaro, C. Romei, A. Biagini, E. Sabini, L. Agate, S. Mazzeo, G. Materazza, S. Sellari-franceschini, A. Ribechini, L. Torregrossa, F. Basolo, P. Vitti, R. Elisei, Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 13, 644–660 (2017)CrossRefPubMed
7.
D. Giuffrida, H. Gharib, Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann. Oncol. 11, 1083–1089 (2000)CrossRefPubMed
8.
N. Besic, B. Gazic, Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution. Thyroid 23, 709–713 (2013)CrossRefPubMed
9.
S. Filetti, C. Durante, D. Hartl, S. Leboulleux, L.D. Locati, K. Newbold, M.G. Papotti, A. Berruti, ESMO Guidelines Committee: Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1856–1883 (2019)CrossRefPubMed
10.
M. Ragazzi, A. Ciarrocchi, V. Sancisi, G. Gandolfi, A. Bisagni, S. Piana, Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol. (2014). https://​doi.​org/​10.​1155/​2014/​790834.
11.
K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas, T.J. Clark Jr., A. Di Cristofano, R. Foote, T. Giordano, J. Kasperbauer, K. Newbold, Y.E. Nikiforov, G. Randolph, M.S. Rosenthal, A.M. Sawka, M. Shah, A. Shaha, R. Smallridge, C.K. Wong-Clark, 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 31, 337–386 (2021)CrossRefPubMedPubMedCentral
12.
S.M. Glaser, S.F. Mandish, B.S. Gill, G.K. Balasubramani, D.A. Clump, S. Beriwal, Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival. Head. Neck 38, E2083–E2090 (2016)CrossRefPubMed
13.
L.J. Wirth, M.S. Brose, E.J. Sherman, L. Licitra, M. Schlumbeger, S.I. Sherman, K.C. Bible, B. Robinson, P. Rodien, Y. Godbert, C. De La Fouchardiere, K. Newbold, C. Nutting, S. Misir, R. Xie, A. Almonte, W. Ye, M.E. Cabanillas, Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients with Anaplastic Thyroid Cancer. J. Clin. Oncol. 39, 2359–2366 (2021)CrossRefPubMedPubMedCentral
14.
J.W. Kunstman, C.C. Juhlin, G. Goh, T.C. Brown, A. Stenman, J.M. Healy, J.C. Rubinstein, M. Choi, N. Kiss, C. Nelson-Williams, S. Mane, D.L. Rimm, M.L. Prasad, A. Hoog, J. Zedenius, C. Larsson, R. Korah, R.P. Lifton, T. Carling, Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum. Mol. Genet. 24, 2318–2329 (2015)CrossRefPubMedPubMedCentral
15.
16.
I. Landa, T. Ibrahimpasic, L. Boucai, R. Sinha, J.A. Knauf, R.H. Shah, S. Dogan, J.C. Ricarte-Filho, G.P. Krishnamoorthy, B. Xu, N. Schutlz, M.F. Berger, C. Sander, S.B. Taylor, R. Ghossein, I. Gangly, J.A. Fagin, Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest 126, 1052–1066 (2016)CrossRefPubMedPubMedCentral
17.
V.C. Sandulache, M.D. Williams, S.Y. Lai, C. Lu, W.N. William, N.L. Busaidy, G.J. Cote, R.R. Singh, R. Luthra, M.E. Cabanillas, Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma. Thyroid 27, 81–87 (2017)CrossRefPubMedPubMedCentral
18.
A. Antonelli, P. Fallahi, S.M. Ferrari, I. Ruffilli, F. Santini, M. Minuto, D. Galleri, P. Miccoli, New targeted therapies for thyroid cancer. Curr. Genomics 12, 626–631 (2011)CrossRefPubMedPubMedCentral
19.
A. Antonelli, S.M. Ferrari, G. Elia, A. Patrizio, P. Fallahi, Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up. Gland Surg. 8, 298–300 (2019)CrossRefPubMedPubMedCentral
20.
B. Xu, T. Fuchs, S. Dogan, I. Landa, N. Katabi, J.A. Fagin, R.M. Tuttle, E. Sherman, A.J. Gill, R. Ghossein, Dissecting anaplastic thyroid carcinoma: A comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 30, 1505–1517 (2020)CrossRefPubMedPubMedCentral
21.
R.M. Quiros, H.G. Ding, P. Gattuso, R.A. Prinz, X. Xu, Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103, 2261–2268 (2005)CrossRefPubMed
22.
V. Subbiah, R.J. Kreitman, Z.A. Wainberg, J.Y. Cho, J.H.M. Schellens, J.C. Soria, P.Y. Wen, C. Zielinski, M.E. Cabanillas, G. Urbanowitz, B. Mookerjee, D. Wang, F. Rangwala, B. Keam, Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J. Clin. Oncol. 36, 7–13 (2018)CrossRefPubMed
23.
A. Smulever, S. Barrio Lower Daniele, G. Damiano, F. Pitoia, Complete surgical resection after Dabrafenib plus Trametinib treatment in a patient with locally advanced and metastatic anaplastic thyroid carcinoma with a BRAF V600E mutation. Thyroid 30, 1224–1225 (2020)CrossRefPubMed
24.
F. Pitoia, A. Smulever, F. Jerkovich, Letter to the Editor: “Foundation OneTM Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy”. J. Clin. Endocrinol. Metab. 105, e3490–e3491 (2020)CrossRef
25.
M.B. Amin, S. Edge, F. Greene, D.R. Byrd, R.K. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer, AJCC Cancer Staging Manual, 8th edn. (2017)
26.
27.
M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, E.T. McFadden, P.P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649–655 (1982)CrossRefPubMed
28.
M. Belló, V.M. Becerril-Montekio, The health system of Argentina. Salud Publica Mex. 53, S96–S108 (2011)PubMed
29.
R.C. Smallridge, L.A. Marlow, J.A. Copland, Anaplastic thyroid carcinoma: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 16, 17–44 (2009)CrossRefPubMed
30.
R.C. Smallridge, J.A. Copland, Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin. Oncol. (R. Coll. Radio.) 22, 486–497 (2010)CrossRef
31.
E. Brignardello, N. Palestini, F. Felicetti, A. Castiglione, A. Piovesan, M. Gallo, M. Freddi, U. Ricardi, G. Gasparri, G. Ciccone, E. Arvat, G. Bocuzzi, Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012. Thyroid 24, 1600–1606 (2014)CrossRefPubMed
32.
N. Prasongsook, A. Kumar, A.V. Chintakuntlawar, R.L. Foote, J. Kasperbauer, J. Molina, Y. Garces, D. Ma, M.A. Neben Wittich, J. Rubin, R. Richardson, J. Morris, I. Hay, V. Fatourechi, B. Mclver, M. Ryder, G. Thompson, C. Grant, M. Richards, T.J. Sebo, M. Rivera, V. Suman, S.M. Jenkins, R.C. Smallridge, K.C. Biblke, Survival in response to multimodal therapy in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 102, 4506–4514 (2017)CrossRefPubMed
33.
J. Wendler, M. Kroiss, K. Gast, M.C. Kreissl, S. Allelein, U. Lichtenauer, R. Blaser, C. Spitzweg, M. Fassnacht, M. Schott, D. Fuhrer, V. Tiedje, Clinical presentation, treatment, and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur. J. Endocrinol. 175, 521–529 (2016)CrossRefPubMed
34.
C. Are, A.R. Shaha, Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann. Surg. Oncol. 13, 453–464 (2006)CrossRefPubMed
35.
A. Maniakas, R. Dadu, N.L. Busaidy, J.R. Wang, R. Ferrarotto, C. Lu, M.D. Williams, G.B. Gunn, M.C. Hofmann, G. Cote, J. Seprling, N.D. Gross, E.M. Sturgis, R.P. Goepfert, S.Y. Lai, M.E. Cabanillas, M. Zafereo, Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol. 6, 1397–1404 (2020)CrossRefPubMed
36.
N.M. Iñiguez-Ariza, S. Jasim, M.M. Ryder, A.V. Chintakuntlawar, J.C. Morris, C.R. Hilger, M.E. Menefee, R.C. Smallridge, N.J. Karlin, C. Alcaino, K.C. Bible, Foundation one genomic interrogation of thyroid cancers in patients with metastatic disease requiring systemic therapy. J. Clin. Endocrinol. Metab. 105, e2346–e2357 (2020)CrossRefPubMedPubMedCentral
37.
J.R. Wang, M.E. Zafereo, R. Dadu, R. Ferrarotto, N.L. Busaidy, C. Lu, S. Ahmed, M.K. Gule-Monroe, M.D. Williams, E.M. Sturgis, R.P. Goepfert, N.D. Gross, S.Y. Lai, G.B. Gunn, J. Phan, D.I. Rosenthal, C.D. Fuller, W.H. Morrison, P. Iyer, M.E. Cabanillas, Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E‐mutated anaplastic thyroid carcinoma. Thyroid 29, 1036–1043 (2019)CrossRefPubMedPubMedCentral
38.
L.J. Wirth, E. Sherman, B. Robinson, B. Solomon, H. Hang, J. Lorch, F. Worden, M. Brose, J. Patel, S. Leboulleux, Y. Godbert, F. Barlesi, J.C. Morris, T.K. Owonikoko, D.S.W. Tan, O. Gautschi, J. Weiss, C. de la Fouchardiere, M.E. Burkard, J. Laskin, M.H. Taylor, M. Kroiss, J. Medioni, J.W. Goldman, T.M. Bauer, B. Levy, V.W. Zhu, N. Lakhani, V. Moreno, K. Evata, M. Nguyen, D. Heirich, E.Y. Zhu, X. Huang, L. Yang, J. Kherani, S.M. Rothenberg, A. Drilon, V. Subbiah, M.H. Shah, M.E. Cabanillas, Efficacy of Selpercatinib in RET-altered thyroid cancers. N. Engl. J. Med 383, 825–835 (2020)CrossRefPubMed
39.
D.S. Hong, S.G. DuBois, S. Kummar, A.F. Farago, C.M. Albert, K.S. Rohrberg, C.M. van Tilburg, R. Nagasubramanian, J.D. Berlin, N. Federman, L. Mascarenhas, B. Geoerger, A. Dowlati, A.S. Pappo, S. Bielack, F. Doz, R. McDermott, J.D. Patel, R.J. Schilder, M. Tahara, S.M. Pfister, O. Witt, M. Ladanyi, E.R. Rudzinski, S. Nanda, B.H. Childs, T.W. Laetsch, D.M. Hyman, A. Drilon, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2, 531–540 (2020)CrossRef
40.
V. Subbiah, R.J. Kreitman, Z.A. Wainberg, J.Y. Cho, J.H.M. Schellens, J.C. Soria, P.Y. Wen, C.C. Zielinski, M.E. Cabanillas, A. Boran, P. Ilankumaran, P. Burgess, T. Romero Salas, B. Keam, Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann. Oncol. 33, 406–415 (2022)CrossRefPubMed
Metadaten
Titel
Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience
verfasst von
Fernanda Bueno
Anabella Smulever
Inés Califano
Jorgelina Guerra
Andrés Del Grecco
Juan Manuel Carrera
Raúl Giglio
Manglio Rizzo
Alejo Lingua
Ana Voogd
María del Carmen Negueruela
Erika Abelleira
Fabian Pitoia
Publikationsdatum
09.01.2023
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2023
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03295-2

Weitere Artikel der Ausgabe 1/2023

Endocrine 1/2023 Zur Ausgabe

Original Article

Patient feedback receiving care using a shared decision making tool for thyroid nodule evaluation—an observational study

Meta- Analysis

Association between the history of abortion and gestational diabetes mellitus: A meta-analysis

Original Article

The prognostic utility of serum thyrotropin in hospitalized Covid-19 patients: statistical and machine learning approaches

Original Article

Impact of microvascular complications on the outcomes of diabetic foot in type 2 diabetic patients with documented peripheral artery disease

Original Article

Follow, consider, and catch: second primary tumors in acromegaly patients

Original Article

Temporal trends in referrals of RET gene carriers for neck surgery to a tertiary surgical center in the era of international management guidelines

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise